Compile Data Set for Download or QSAR
Report error Found 380 Enz. Inhib. hit(s) with all data for entry = 11094
TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474574(US10849883, Compound 3d | US11559515, Compound 3d)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474575(US10849883, Compound 4d | US11559515, Compound 4d)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474577(US10849883, Compound 6d | US11559515, Compound 6d)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474583(US10849883, Compound 12d | US11559515, Compound 12...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474584(US10849883, Compound 13d | US11559515, Compound 13...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474585(US10849883, Compound 14d | US11559515, Compound 14...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474586(US10849883, Compound 15d | US11559515, Compound 15...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474589(US10849883, Compound 18d | US11559515, Compound 18...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474591(US10849883, Compound 20d | US11559515, Compound 20...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474592(US10849883, Compound 21d | US11559515, Compound 21...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474593(US10849883, Compound 22d | US11559515, Compound 22...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474594(US10849883, Compound 23b | US11559515, Compound 23...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474603(US10849883, Compound 32b | US11559515, Compound 32...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM589769(1-(2-(((2S,3R)-1-((3-chloro-2-fluorobenzyl)amino)-...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474610(US10849883, Compound 39f | US11559515, Compound 39...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474614(US10849883, Compound 43g | US11559515, Compound 43...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474617(US10849883, Compound 46b | US11559515, Compound 46...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474618(US10849883, Compound 47d | US11559515, Compound 47...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474621(US10849883, Compound 142f | US11559515, Compound 1...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474622(US10849883, Compound 50d | US11559515, Compound 50...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474624(US10849883, Compound 52b | US11559515, Compound 52...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474629(US10849883, Compound 57d | US11559515, Compound 57...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474636(US10849883, Compound 43f | US11559515, Compound 43...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474639(US10849883, Compound 66d | US11559515, Compound 66...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474640(US10849883, Compound 67a | US11559515, Compound 67...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474648(US10849883, Compound 75b | US11559515, Compound 75...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474651(US10849883, Compound 78a | US11559515, Compound 78...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474654(US10849883, Compound 143e | US11559515, Compound 1...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474655(US10849883, Compound 149f | US11559515, Compound 1...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474656(US10849883, Compound 82e | US11559515, Compound 82...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474657(US10849883, Compound 83d | US11559515, Compound 83...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM589824(US11559515, Compound 84e)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474660(US10849883, Compound 86d | US11559515, Compound 86...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474661(US10849883, Compound 87a | US11559515, Compound 87...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474662(US10849883, Compound 88b | US11559515, Compound 88...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474667(US10849883, Compound 93b | US11559515, Compound 93...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474668(US10849883, Compound 94b | US11559515, Compound 94...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474718(US10849883, Compound 144a | US11559515, Compound 1...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474720(US10849883, Compound 146b | US11559515, Compound 1...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474740(US10849883, Compound 167b | US11559515, Compound 1...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474756(US10849883, Compound 181b | US11559515, Compound 1...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474810(US10849883, Compound 231b | US11559515, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474811(US10849883, Compound 199a | US11559515, Compound 1...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474824(US10849883, Compound 252a | US11559515, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474842(US10849883, Compound 254b | US11559515, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM590036(US11559515, Compound 284g)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474875(US10849883, Compound 297a | US11559515, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474939(US10849883, Compound 359f | US11559515, Compound 3...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474573(US10849883, Compound 2f | US11559515, Compound 2f)
Affinity DataIC50: 5.50E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM474576(US10849883, Compound 5d | US11559515, Compound 5d)
Affinity DataIC50: 5.50E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 380 total ) | Next | Last >>
Jump to: